公开(公告)号：US10377988B2

公开(公告)日：2019-08-13

申请号：US15533103

申请日：2016-01-22

Applicant: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT

Inventor： Mark Rubinstein ,  David Cole

IPC: C12N5/0783 ,  A61K35/17 ,  A61K38/17 ,  A61K38/20 ,  C07K14/715 ,  C12N15/85 ,  C07K14/705

Abstract: Cells, such a T-cells, are provided that comprise cytokine receptors having increased activity in response to their ligand. For example, cell can comprise IL-2 and/or IL-15 receptors having increased surface expression or signaling activity. Cells of the embodiments have a significant growth advantage in the presence of cytokines and can be used, e.g., for enhanced adoptive cell transfer therapies.

公开(公告)号：US10370328B2

公开(公告)日：2019-08-06

申请号：US15565820

申请日：2016-04-28

Applicant: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT ,  U.S. DEPARTMENT OF VETERANS AFFAIRS

Inventor： Craig C. Beeson ,  Christopher C. Lindsey ,  Baerbel Rohrer ,  Yuri Karl Peterson

IPC: C07D209/38 ,  C07D401/06 ,  C07D403/06 ,  C07D209/36 ,  C07D403/12 ,  C07D401/14 ,  C07D401/12 ,  C07D403/14 ,  C07D405/06 ,  C07D413/06 ,  C07D498/04 ,  A61P27/02 ,  C07D209/34 ,  C07D405/12 ,  C07F9/572

Abstract: Provided herein are compounds of the formula (I) as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of degenerative diseases and disorders.

公开(公告)号：US20190127483A1

公开(公告)日：2019-05-02

申请号：US16089498

申请日：2017-03-30

Applicant: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT

Inventor： Zihai LI

IPC: C07K16/34 ,  A61K31/675 ,  C07K16/28 ,  A61K31/7076 ,  A61K9/00 ,  A61P35/00 ,  C07K16/30

Abstract: Isolated or recombinant monoclonal antibodies that bind to GARP are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer. Further provided herein are methods and compositions for treating cancer in an individual comprising administering to the individual an effective amount of an anti-platelet agent and a T cell therapy.

公开(公告)号：US20190125796A1

公开(公告)日：2019-05-02

申请号：US16095791

申请日：2017-04-28

Applicant: MUSC Foundation for Research Development

Inventor： Shikhar Mehrotra ,  Michael I. Nishimura ,  Pravin Kesarwani ,  Shilpak Chatterjee

IPC: A61K35/17 ,  C12N5/0783 ,  A61P35/00 ,  A61K38/20 ,  A61K38/06 ,  A61K31/381 ,  A61K31/401 ,  A61K38/43

Abstract: The present invention relates to an adoptive T cell therapy using cells generated by genetically or biochemically reprogramming T cells to produce T memory stem cells (Tscm) that persist longer in vivo and are superior anti-tumor effector cells.

公开(公告)号：US20180371542A1

公开(公告)日：2018-12-27

申请号：US16019091

申请日：2018-06-26

Applicant: MUSC Foundation for Research Development

Inventor： Raymond F. Anton

IPC: C12Q1/6876 ,  A61K31/485 ,  A61P25/32

Abstract: Provided are methods for treating alcohol use disorders using opioid receptor antagonists. In some embodiments, the presently disclosed methods include assaying nucleic acid from a subject regarding the subject's genotype with respect to the COMT and OPRM1 genes and administering or not administering an opioid receptor antagonist to the subject on the basis therefore. Also provided are methods for detecting susceptibility to an opioid receptor antagonist therapy for disorders associated with opioid receptor activity and methods for identifying and treating human subjects having susceptibility to opioid receptor antagonist therapies for disorders associated with opioid receptor activity.

公开(公告)号：US20180179263A1

公开(公告)日：2018-06-28

申请号：US15579690

申请日：2016-06-03

Applicant: iBio, Inc. ,  Novici Biotech LLC ,  MUSC Foundation for Research Development

Inventor： Carol Feghali-Bostwick ,  Terence E Ryan ,  Hal S. Padgett ,  Matthew McGee

IPC: C07K14/78 ,  C12N15/74 ,  C12N15/82

CPC classification number: C07K14/78 ,  A61K38/00 ,  A61K38/13 ,  A61K45/06 ,  C07K2319/30 ,  C12N15/743 ,  C12N15/8257 ,  A61K2300/00

Abstract: Materials and methods for using polypeptides containing fragments and variants of endostatin to treat fibrosis are described herein.

公开(公告)号：US20180071363A1

公开(公告)日：2018-03-15

申请号：US15825423

申请日：2017-11-29

Applicant: MUSC Foundation for Research Development

Inventor： Gautam GHATNEKAR ,  Robert GOURDIE ,  Jane JOURDAN

IPC: A61K38/17 ,  C07K14/435 ,  C07K14/705

CPC classification number: A61K38/177 ,  A61K38/07 ,  A61K38/08 ,  A61K38/10 ,  A61K38/1709 ,  A61K38/1767 ,  A61K45/06 ,  A61L31/08 ,  A61L2430/34 ,  C07K5/10 ,  C07K7/06 ,  C07K7/08 ,  C07K14/43581 ,  C07K14/47 ,  C07K14/705 ,  C07K2319/01 ,  C07K2319/10

Abstract: Provided herein are compositions and methods for use in promoting wound healing and tissue regeneration following tissue injury in a subject.

公开(公告)号：US20170205320A1

公开(公告)日：2017-07-20

申请号：US15320796

申请日：2015-07-10

Applicant: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT

Inventor： Kathryn LINDSEY ,  Wanda SHOTSBERGER ,  Patricia M. HOUSER ,  Jack YANG

IPC: G01N1/36 ,  G01N1/28 ,  G01N1/30

CPC classification number: G01N1/36 ,  G01N1/286 ,  G01N1/30 ,  G01N2001/305 ,  G01N2001/364

Abstract: Embodiments disclosed herein relate to methods and apparatus for cell block preparation of cytology specimens. Specific embodiments relate to methods and apparatus for formal-in fixed paraffin embedded cell block preparation of cytology specimens.

公开(公告)号：US20170100047A1

公开(公告)日：2017-04-13

申请号：US15291448

申请日：2016-10-12

Applicant: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT

Inventor： Jonathan Edwards ,  Jessica Barley ,  Mark Semler

IPC: A61B5/04 ,  A61B5/00

CPC classification number: A61B5/04001 ,  A61B5/0022 ,  A61B5/0492 ,  A61B5/6849 ,  A61B5/688 ,  A61B5/7203 ,  A61B2505/05

Abstract: A needle electrode fixation device is configured to secure a transdermal needle electrode to a patient. The device includes a base having a body that defines a first portion and a second portion. The first and second portions are rotatable relative to each other. The first portion defines a channel configured to fit a portion of the transdermal needle electrode. The second portion defines a recess configured to fit a tip of the needle electrode. The device further includes an adhesive layer configured to affix the base to the patient.

公开(公告)号：US09556207B2

公开(公告)日：2017-01-31

申请号：US14526721

申请日：2014-10-29

Applicant: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT

Inventor： Craig C. Beeson ,  Christopher C. Lindsey ,  Yuri K. Peterson ,  Baerbel Rohrer

IPC: C07D231/14 ,  C07F7/10 ,  C07D403/06 ,  C07D403/04 ,  C07D401/14 ,  C07D401/04 ,  C07D401/06 ,  C07F7/08

CPC classification number: C07F7/0814 ,  C07D231/14 ,  C07D401/04 ,  C07D401/06 ,  C07D401/14 ,  C07D403/04 ,  C07D403/06 ,  C07F7/10

Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of degenerative diseases and disorders.

Abstract translation: 本文提供式（I）的化合物及其药学上可接受的盐，其中取代基如说明书中公开的那些。 这些化合物和含有它们的药物组合物可用于治疗退行性疾病和病症。